

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

## Doxecitine-doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484

### **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
UCB Pharma (doxecitine	All Wales Inherited Metabolic Disease
doxribtimine)	Service Cardiff
	All Wales Therapeutics and Toxicology
Patient/carer groups	Centre
Beacon	Allied Health Professionals Federation
Gene People	Board of Community Health Councils in
Genetic Alliance UK	Wales
Lily Foundation	British National Formulary
Metabolic Support UK	Care Quality Commission
South Asian Health Foundation	Cell and Gene Therapy Catapult
Specialised Healthcare Alliance	<ul> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> </ul>
Healthcare professional groups	Healthcare Improvement Scotland
Association of Genetic Nurses &	Medicines and Healthcare products
Counsellors	Regulatory Agency
British Society for Gene and Cell	<ul> <li>National Association of Primary Care</li> </ul>
Therapy	National Pharmacy Association
British Society for Genetic Medicine	NHS Confederation
British Society for Human Genetics	NHS Wales Joint Commissioning
Neonatal and Paediatric Pharmacists	Committee
Group	Scottish Medicines Consortium
Royal College of General Practitioners	Welsh Government
Royal College of Nursing	
Royal College of Pathologists	Possible comparator companies
<ul> <li>Royal College of Paediatrics &amp; Child Health</li> </ul>	None
Royal College of Physicians	Relevant research groups
Royal Pharmaceutical Society	Cochrane Cystic Fibrosis & Genetic
Royal Society of Medicine	Disorders Group
UK Clinical Pharmacy Association	Genomics England
United Kingdom National Screening	MRC Clinical Trials Unit
Committee	National Institute for Health Research
	Associated Public Health groups
	Public Health Wales

Provisional stakeholder list for the evaluation of doxecitine-doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Others</li> <li>Department of Health and Social Care</li> <li>Metabolic Medicine Department,         Great Ormond Street Hospital for         Children NHS Foundation Trust</li> <li>NHS England</li> <li>NHS Rare Mitochondrial Disorders         Service (Newcastle Mitochondrial         Service, University College London         Hospital NHS Highly Specialised         Service for Rare Mitochondrial         Disorders &amp; Oxford University         Hospitals Rare Mitochondrial         Disorders Service)</li> <li>The Charles Dent Metabolic Unit,         University College London Hospital         NHS Foundation Trust</li> <li>The Mark Holland Metabolic Unit,         Salford Royal Hospital, Northern Care         Alliance NHS Foundation Trust</li> <li>Willink Biochemical Genetics Unit,         Manchester University NHS         Foundation Trust</li> </ul>	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484

Issue date: May 2025





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.